Manufacturing and Analytical Characterization - Chemical
Category: Poster Abstract
Ken (Zhengkun) Yu, MS
Supervisor, Analytical Development
Thermo Fisher Scientific
Mississauga, Ontario, Canada
Ken (Zhengkun) Yu, MS
Supervisor, Analytical Development
Thermo Fisher Scientific
Mississauga, Ontario, Canada
Monica Choi, Ph.D.
Mirati Therapeutics
San Diego, California, United States
Lee Fang, MS
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
Linus Zeng, MS
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
John Jiang, Ph.D.
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
Nitin Tailor, MS
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
Quazi Ahmed, MS
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
Geoffrey P. Carr, Ph.D.
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
William Yu, MS
Patheon, Part of Thermo Fisher Scientific
Mississauga, Ontario, Canada
Figure 1, Dissolution Results Generated with Fisher SDS from December 2020 to Jun 2021
Figure 2, Dissolution Results Generated with Sigma SDS from August 2021 to Present
Figure 3, CNHCN, Dissolution Results with Different Warm-up Time, MRTX849 IR tablets, 200 mg